This contrasts with the efficacy of this therapy in ameliorating intestinal mucositis, cancer cachexia, and anthracycline-induced cardiotoxicity [82], which may suggest that the efficacy of IL-1 inhibition in humans may be influenced by timing, dosing, and the specific context and by the dual roles of NLRP3 inflammasome in these disorders. Here, NLRP3 is linked to cancer.